Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "Hyderabad"

255 News Found

STEER World appoints Dhiraj Tiwari as CFO
People | September 04, 2024

STEER World appoints Dhiraj Tiwari as CFO

Dhiraj brings 20+ years of extensive executive-level financial expertise across various industries including Pharma, Media, Retail, and FMCG


Thyrocare to acquire diagnostic and pathological services business of Vimta Labs
News | August 31, 2024

Thyrocare to acquire diagnostic and pathological services business of Vimta Labs

Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025


Gland Pharma posts 16% revenue growth in Q1 FY25
News | August 07, 2024

Gland Pharma posts 16% revenue growth in Q1 FY25

The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore


SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr
News | August 06, 2024

SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr

SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024


Aurobindo Pharma receives USFDA approval for Estradiol Vaginal Inserts USP, 10 mcg
Drug Approval | August 06, 2024

Aurobindo Pharma receives USFDA approval for Estradiol Vaginal Inserts USP, 10 mcg

The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA


Dr. Reddy's receives positive CHMP opinion from EMA for its proposed Rituximab biosimilar
Drug Approval | July 30, 2024

Dr. Reddy's receives positive CHMP opinion from EMA for its proposed Rituximab biosimilar

Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance


Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr
News | July 29, 2024

Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr

Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024


USFDA inspects Gland Pharma’s Dundigal facility
Drug Approval | July 26, 2024

USFDA inspects Gland Pharma’s Dundigal facility

The inspection was concluded with two 483 observations


Fostering closer ties between industry & academia imperative for sustainable growth
News | July 25, 2024

Fostering closer ties between industry & academia imperative for sustainable growth

The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future


Suven Pharmaceuticals gets Form 483 from with two observations from USFDA for Casper Pharma
Drug Approval | July 14, 2024

Suven Pharmaceuticals gets Form 483 from with two observations from USFDA for Casper Pharma

The company will address these observations within the stipulated timeline